Clinical Trial Update: Study of Pegylated Liposomal Doxorubicin and Temsirolimus in Patients With Advanced Hepatocellular Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating pegylated liposomal doxorubicin and temsirolimus for advanced hepatocellular carcinoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Doxil (liposomal doxorubicin)
• Torisel (Temsirolimus)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Liver Neoplasms | Phase 2 | Status: WITHDRAWN